[_] TRANSITION
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
This Annual Report on Form 10-K is hereby amended solely
in respect of the Company’s Consolidated Financial Statements and Supplementary Data and the notes thereto. Except as so
amended, nothing in the Company’s Annual Report on Form 10-K for its fiscal year ended June 30, 2019, has been amended and
the Company does not undertake any responsibility to update any other sections thereof.
PART
I
Item 1. Business
Company’s History
Wearable Health Solutions,
Inc. (Formerly known as Medical Alarm Concepts Holding, Inc.) (the "Company" or "Wearable Health") was formed
in June 2008 and, on June 24, 2008. The Company acquired 100% of the membership interests in Medical Alarm Concepts, LLC, a Delaware
limited liability corporation.
The principal executive
offices of the Company are located at 200 West Church Road, Suite B, King of Prussia, PA 19406.
Company Overview
The Company manufactures
medical alarm devices that are used to summon help in the event of an emergency. While these devices are primarily designed for
the elderly, there is also a market for those who are physically disabled, as well as for persons living alone.
The Company was organized
in mid-2008. The operation was financed with a considerable amount of toxic convertible debt. This type of financing, along with
several other issues, prevented the Company from realizing a robust growth rate for its first few years of operation. Since that
time, considerable management time has been spent and investor money utilized to turn the Company's operation around.
Our flagship product
is called the MediPendant®, which is a personal emergency alarm that is used to summon help in the event of an emergency at
home. Currently, approximately 60% of all medical alarms being sold in the United States are first-generation technologies that
require the user to speak and listen through a central base station unit. The MediPendant®, however, offers a product that
has the speaker in the pendant, enabling the user to simply speak and listen directly through the pendant in the event of an emergency.
The Company also manufacture
the iHelp™ mobile medical alarm device. The iHelp™ is a next- generation medical alarm that utilizes T-Mobile's 2G
network. Users of the iHelp™ mobile medical alarm can take the device with them wherever there is cellular service. There
is no base station and the iHelp™ only requires a cellular signal in order to work.
The company has invested
time, manpower, and money into the development of this product. On September 30, 2014, the company signed an agreement for a $300,000
line of credit to enable it to launch the iHelp™, and to build the infrastructure that allowed the Company to buy and track
air time from T-Mobile for cellular operation of this unit. The credit line was increased to $500,000 in January 2015. The iHelp™
has enhanced features and functions including an advanced GPS system, the ability to remotely locate a loved one, and a dealer
portal that enables dealers to manage their own iHelp™ customer base. A significant amount of time was spent on the backend
systems, including the dealer portal. iHelp™ dealers have significant benefits, most importantly the ease of use in ordering
product, activating and deactivating customers, tracking their customer usage, and creating and printing a variety of reports
to assist in billing and collecting revenues. The iHelp™ dealer program is a turn-key program that offers the dealer the
opportunity to provide his/her customers with the latest products without having to change his/her own backend.
We are in the process
of discontinuing the iHelp™ and implementing a new product called the iHelp+ 3G™. The iHelp+ 3G™ is a cellular
medical alert system that operates on a 3G network. In March 2016 and May 2016 the company raised an additional $612,500 and $425,000
to further develop the 3G product. Initially, it will be operating on the AT&T network (GSM - Global), and ultimately it will
be able to operate on the Verizon (CDMA - USA) network as well. It is Bluetooth and Wi-Fi enabled. It has a much broader reach
than the iHelp™, as well as additional functions, such as fall detection and geo-fencing (ability to pre-set an area and
alert loved ones if the user leaves or enters the pre-set area). As of this date we have gained FCC, CE, and PTCRB approval. Expected
product launch date is now Dec 2016.
It is planned
that by the end of 2017 the iHelp+3G™ will be used as the communication device for Low Energy Bluetooth 4.0-enabled
devices, and used for collecting and sending vital sign data, in any requested manner, to encrypted HIPAA-compliant cloud
servers for access by proper parties.
New Product
Development
The design and development
of wearable 'biosensor' devices, such as the iHelp+3G™ for health and wellness, has garnered much attention in the public
and healthcare community during the last few years. This is primarily motivated by increasing healthcare costs and propelled by
recent technology advances in miniature bio-sensing devices, micro-computing technology, and wireless communications. The advance
of wearable sensor-based systems will potentially transform the future of "telehealth", personal emergency response
(PERS, mPERS) and remote monitoring, by enabling ubiquitous, convenient-to-use, cost-effective and proactive personal health management
with real and near real-time monitoring and archiving of personal safety, health, and environmental conditions.
Beyond the recent emergence
of smart mobile wireless and geographic location solutions, these systems will integrate via Bluetooth low energy 4.0 and other
technologies with FDA approved medical devices and biosensors. The Company will be able to collect data on vital signs, send this
data to HIPAA compliant servers in the cloud, and allow access by caregivers, nurses, doctors, hospitals, and other health organizations.
This process can facilitate low- monthly-cost wearable solutions for the implementation of monitoring of users, all day and anywhere,
for emergency, health, and activity status changes. This evolution will change the face of the traditional PERS device into a
WHAM (Wearable Health& Alarm Monitoring) market.
Market Background
Living arrangements
have changed greatly in the United States among older people and other potentially vulnerable segments of the population, including
those with physical disabilities and/or medical conditions. During the 20th century, one of the most dramatic changes in the lives
of the aging in the United States was the rise of the number of aging people living at home alone. In 1910, for example, only
12% of widows age 65 or older lived alone. In 1970, this figure was 70% and today it is estimated to be impressively higher.
In the 21st century,
this trend has gained momentum and become stronger than ever, with more of the aging and medically at risk population living alone
at present than at any other time in the past, especially with the rise of the aging Baby Boomer population. The Baby Boomers,
those born between 1946 and 1964, started turning 65 years old in 2011, with the number of older people set to increase dramatically
during the 2010 to 2030 time period. According to a 2009 analysis of U.S. Current Population Survey data, "between 2010 and
2030, the number of people age 65 and older is projected to grow by 31.7 million or 79.2%." Thus, the older population in
2030 is projected to be twice as large as in 2000, growing from 35 million to 71.5 million, representing 20% of the total U.S.
population around the year 2030.
This social dynamic
of a rising older population is true in both the United States as well as in many developed nations worldwide. Likewise, social
change, technological advancements, and general lifestyle choices have promoted increased independence and the ability to live
alone among other potentially vulnerable segments of the population such as those with physical disabilities or medical conditions.
These groups can be especially susceptible to health problems and concerns for their physical wellbeing. Experts and even common
sense agree that in order to help facilitate independence and safety, more help is needed to provide these people with a point
of contact in case of emergency, or the benefit of support in a time of need. It was in response to this situation that the personal
emergency response systems (PERS) industry emerged in the United States and developed the first personal medical alarm. The most
obvious and common use for personal medical alarms is as a safeguard for the aged and persons with certain medical conditions,
in case of an age or health related incident that requires immediate attention, and in which the victim is unable to reach out
for assistance via traditional means, including the ability to make a telephone call.
Effective personal
emergency response systems with their emergency alert capabilities, are a key technology solution that can greatly help the vulnerable
segment of the population live a more free and active life while maintaining the security of being able to access immediate assistance
as needed. In fact, there has been a boom in the PERS market in recent years because of the growing aging population worldwide.
According to Forrester Research, Inc., the PERS market in the United States has grown at double digit rates, from approximately
$350 million in 2004 to $2 billion in 2012 and increasing every year thereafter.
Today, however, while
the PERS industry has been around for a long time, much of the technology within the industry has unfortunately remained stagnant.
Many of the original PERS solutions are still designed today to provide alerts whereby a push of a button simply triggers a call
center operator to respond by calling the device user at home, with two-way voice communication done through a centralized speaker
box and not the actual device itself. Thus, traditional PERS solutions currently on the market offer communication between user
and a call center only through a speaker box. This greatly inhibits the user's freedom and limits their mobility to an area near
the speaker box.
Mobile medical alerts
have recently been introduced to the market. They are designed for the younger and more active person with medical issues, and
also the active elderly adult.
And with the emergence
of telehealth and biosensor technology, the market is changing again, to an even younger people with medical issues that need
to be tracked on a regular basis.
Wearable Health Solutions
offers a wide range of solutions for the user from a simple at home medical alarm to a mobile device that enables the user to
get help anywhere they go. With the introduction of the telehealth product by the end of 2017, users will be able to get help,
before they even know they need it.
Market Opportunity
The healthcare industry
is the largest industry in the world, with the home healthcare market in developed countries in particular growing rapidly, driven
in part by aging baby boomers and a growing shift toward moving some types of healthcare away from the hospital and into the home.
These trends help make
the home healthcare sector an increasingly attractive market for successful companies that offer effective solutions in the PERS
industry space. The most obvious and common use for personal medical alarms is as a safeguard for the aged and persons with certain
medical conditions, not only in case of an age or health related incident that requires immediate attention, but in which the
victim is unable to reach out for assistance via traditional means, including the placement of a telephone call. While very few
things can prevent falls by aged persons or other unforeseen medical emergencies, medical alarms mitigate the potential harm and
expensive hospital stays done by initiating a timely response to such an incident. And tracking devices, like the iHelp+3G™
for wearable biosensors will be able to monitor people with pre-existing conditions.
In fact, there has
been a boom in the PERS market in recent years because of the growing aging population worldwide and in the United States in particular.
According to the U.S. Census Bureau, the number of people over 65 in the United States is set to jump from approximately 34 million
today to approximately 65 million in 2025. By 2050, this number is projected to reach 86.7 million, with many of them living at
home or in an alternative home-type environment. Worldwide, this figure number is expected to double from some 550 million people
currently at age 65 years old to over 1.2 billion seniors by the time period around the year 2025.
Not surprisingly, experts
in the health care industry expect many of these seniors will want to continue living independently at home for as long as possible.
Likewise, more than any aging generation of the past, this population is expected to be more technology-savvy as consumers of
healthcare are very interested in playing an active role in personally managing their health and well-being. Importantly, they
will likely look to technologies that help them gain access to medical care while being able to remain independent and outside
a hospital environment.
Effective personal
emergency response systems (PERS), with their emergency alert capabilities, are a key technology solution that can greatly help
the vulnerable segment of the population live a more free and active life while maintaining the security of being able to access
immediate assistance as needed. According to Forrester Research, Inc., the PERS market in the United States has grown at double
digit rates, from approximately $350 million in 2004 to $2 billion in 2012 and increasing every year thereafter.
According to statistics
from some of the industry's largest providers of traditional PERS solutions, customers of these emergency alert systems are typically
individuals over the age of 75 years old whom are predominantly female and live alone, with the actual buyers of PERS systems
often being the end user's children who purchase the medical alarms for their parents.
Regarding purchases
of PERS solutions worldwide, the large majority of customers currently pay for their PERS products out-of-pocket, with government
reimbursement for PERS items varying from country to country. In the United States, for example, 25% of PERS sales were government
reimbursed in 2004, compared to 35% in Germany, just over 50% in France and nearly 100% in the United Kingdom. Furthermore, it
is estimated government reimbursement for PERS will ramp up in a number of countries, further fueling demand for these products.
Interestingly, as an
approximation of the potential PERS market size in the United States, Lifeline Systems, Inc., the founder of the PERS industry
in the U.S. approximately 35 years ago, served 250,000 users in the United States and Canada around the time frame of 1992. Today,
Philips Medical Systems' acquisition of Lifeline Medical Alarm has positioned it as the largest provider of traditional PERS systems
with over 700,000 monitored accounts, implying that the total market size of users is likely much larger.
Sales and
Marketing
The
company's marketing efforts are focused in four main areas
|
i.
|
Internet sales & marketing,
|
|
iii.
|
wholesale distribution and
|
|
iv.
|
International markets.
|
1) Internet Sales & Marketing
The Company markets the MediPendant®
through its website at www.MediPendant.com and its iHelp™ mobile medical alarm to dealers at www.ihelpalarm.com. Due to the
complex sales process for medical alarms, which often require several phone calls among the end user customer's family members
before a decision is reached, the MediPendant® and iHelp™ websites are used mainly for informational purposes with the
actual sale typically taking place over the phone with one of our customer service representatives or one of our many dealers.
The company uses a variety of techniques, such as Internet paid ad campaigns and social media, in order to drive web traffic to
the websites, and initiate potential customer sales calls.
2) Retail Distribution
During 2012, the company announced
its plans to promote the MediPendant® product utilizing an e-commerce marketing strategy program designed specifically for
Costco Wholesale Corporation and its members. Costco began offering the MediPendant® to its customers via its website during
the spring of 2012.
3) Wholesale Distribution
The Company currently has
several relationships with wholesalers who resell the MediPendant® and the iHelp™ in conjunction with their own monitoring
services. The company believes its relationships with its strategic partners is good. The company is currently in discussions with
several other wholesale groups looking to distribute our products through their own independent channels. With the introduction
of the iHelp+ 3G™, Wearable Health Solutions will be selling only through Wholesale Distribution and in International Markets.
4) International Markets
The Company also distributes
its products in a wholesale manner to selected international markets. To date, the company has made sales in Denmark, Ireland,
Bermuda, and the People's Republic of China. There has recently been a lot of International interest in the company's new iHelp+
3G™, and the company plans to distribute its product initially in Canada and Europe, and expand from there.
Competition
The market for Personal
Emergency Response Systems (PERS) is highly fragmented. Because the vast majority of the market participants are private corporations,
only limited information about competitors is available.
The vast majority
of competitors market first generation PERS systems that rely on a centralized base station for communication between the
user and the monitoring center. The second largest of these market participants is believed to be Life Alert, which was
founded in 1987. The largest participant is thought to be Philips Medical Systems, which several years ago purchased Lifeline
Medical Alarms. Additionally, there are dozens of smaller organizations marketing PERS devices and monitoring services.
Mobile Medical Alerts have recently been introduced to the market. They are designed for the younger and more active person
with medical issues and also the active elderly adult.
Termination of Patent
Purchase Agreement and New Patent Licensing Agreement
On July 10, 2008, the
Company entered into a Purchase Agreement and Patent Assignment Agreement (the "Agreement") effective July 31, 2008.
The Company was obligated to pay the seller $2,500,000 on June 30, 2012. The Agreement specifies interest of 6% payable monthly,
commencing on July 31, 2008. The seller had the right to reacquire all patents and applications if payment was not made on June
30, 2012; however, this agreement has been extended quarterly since June 30, 2012. The patent purchase agreement refers to patent
#RE41845 and RE41392. The scope of the patents are as follows: A personal emergency communication system includes a user-carried
portable communication unit having a single button, which when depressed by the user, wirelessly sends a call request signal to
a base unit. The base unit initiates a telephone call through a dial-up network to an emergency response center and places an
operator at the emergency center responder in wireless voice communication with the portable unit when the call is connected.
The telephone number to be called can be stored in at least one of the portable unit and the base unit. A speech synthesizer operating
in combination with automated voice messages stored in at least one of the base unit and portable unit system memory are used
to advise the user of the status of the call, and to provide the user with verbal confirmation that functional systems of the
base unit are operating properly.
In June 2015, the
Company made a decision to terminate its patent agreement with Nevin Jenkins, the patent holder. Mr. Jenkins and the Company
agreed to a new revised licensing agreement whereby the company still has the ability to order and sell product utilizing the
patent. The company feels that the old agreement was too costly, and money would be better served based on its decision of
investing in more cellular type mPERS devices. Its new agreement with Mr. Jenkins will enable the Company to continue selling
the MediPendant® based on a cost plus structure.
Products
The Company's primary focus
is the sale of its medical alarm and safety alert devices, which are some of the most advanced systems on the market today.
a) MediPendant®
MediPendant® is
the Company's traditional medical alarm product and the world's first monitored two-way voice speakerphone pendant for the PERS
(personal emergency response) industry. It allows the user to speak and listen to the operator directly through the pendant. Wearable
Health Solutions' alarm pendant also offers superior range radio frequency capabilities and an enhanced communication range that
enable the user to move freely in and about the home, including up to an extended range that is revolutionary in the PERS industry.
Specifically, the MediPendant® system enables the device wearer to move up to 600+ feet (line of sight) away from the main
base station, a distance that far exceeds competitive offerings on the market today that instead require the user to be within
speaking distance of the base station box, a situation that may not be conducive to an emergency if the end user is not at the
base station.
As part of the MediPendant®
product offering, users receive Wearable Health Solutions' two- way communication pendant, base station unit and a subscription
to the Company's around- the-clock personal response service monitoring center.
Emergency calls
made through the Company's MediPendant® device are always handled by certified operators who are available around the
clock 24-hours a day and guaranteed to remain on the line with MediPendant® subscribers until the problem is resolved
and/or help arrives. Operators are trained to immediately assess the situation and can either connect the caller to a
loved-one or dispatch medical personnel to the user's location. All emergency operators are prepared to bring calm,
professional, knowledgeable insight to any situation. Additionally, the call center can also maintain an important list of
personal information for all MediPendant® users that includes an updated list of medications, health information and the
subscriber's contact information including home address for location and dispatch purposes. This personal information and
medical history are securely stored by the monitoring center and can be provided to the dispatched authority and emergency
responders as necessary.
b) iHelp™
The company recently announced
the launch of a new, advanced medical alarm device called the iHelp™. The iHelp™ is an advanced mobile medical alert
system, designed to be easy to use, lightweight yet durable, but with significantly advanced features. The company has invested
time, manpower, and money into the development and launch of this product. The iHelp™ has enhanced features and functions
including an advanced GPS system, the ability to remotely locate a loved one, voice prompts, and a dealer portal that enables dealers
to manage their own iHelp™ customer base. A significant amount of time was spent on the back end systems, including the dealer
portal. iHelp™ dealers have significant benefits, most importantly the ease of use in ordering product, activating and deactivating
customers, tracking their customer usage, and creating and printing a variety of reports. The iHelp™ dealer program is a
turn-key program that offers the dealer the opportunity to provide his/her customers with the latest products without having to
change his/her own "back end" systems. With the introduction of the new and greatly improved iHelp+ 3G™ unit, the
iHelp™ will no longer be produced.
c) iHelp + ™ 3G
The iHelp+ 3G™ is currently
in the final approval stage and is expected to be available to the marketplace by December 2016. The iHelp+ 3G™ is similar
to the iHelp™ in that it is an mPERS product. However, the iHelp+ 3G™ will have more advanced features and functions,
including the ability to detect if the wearer of the unit falls such as in the shower, have Geo-Fencing and Tracking ability, will
operate on the "3G" networks, and be telehealth enabled via blue tooth low energy 4.0. The unit will have superior audio
quality, an extended battery life, and will operate on GSM networks allowing for use with AT&T providers both domestically
and internationally (with AT&T partners), therefore enabling extended coverage almost anywhere the user may go.
Item 1A. Risk Factors
The information to be reported
under this Item is not required of smaller reporting companies.
Item 1B. Unresolved Staff
Comments
Not Applicable
Item 2. Properties
The principal place of business
of the Company is situated at 200 West Church Road Suite B, King of Prussia, PA 19406. This office is leased. The management believes
that the facilities it is using now are adequate and suitable for business requirements.
Item 3. Legal Proceedings
The Company is
not presently a party to any litigation nor, to our knowledge, is any litigation threatened against it, which may materially
affect its business or its assets.
Item 4. Mine Safety Disclosures
Not Applicable
NOTES TO THE FINANCIAL STATEMENTS
As at June 30, 2019 and 2018
Note 1 -- Nature and Continuance of Operations
Wearable Healthcare Solutions Inc. (the “Company”)
was incorporated as Medical Alarm Concepts Holding, Inc. on June 4, 2008 under the laws of the State of Nevada. The Company was
formed for the sole purpose of acquiring all of the membership units of Medical Alarm Concepts LLC, a Pennsylvania limited liability
company (“Medical LLC”). On May 26, 2016, the Company filed its Amended and Restated Articles of Incorporation with
the Secretary of State of the State of Nevada to change its name from “Medical Alarm Concepts, Inc.” to “Wearable
Health Solutions Inc.”
The Company is primarily engaged in utilizing new technology
in the medical alarm industry to provide 24-hour personal response monitoring services and related products to subscribers with
medical or age-related conditions.
Note 2 – Summary of Significant Accounting Policies
Basis of Presentation – The accompanying financial
statements are prepared in accordance with Generally Accepted Accounting Principles in the United States of America (“GAAP”).
The preparation of these financial statements requires our management to make estimates and assumptions about future events that
affect the amounts reported in the financial statements and related notes. Future events and their effects cannot be determined
with absolute certainty. Therefore, the determination of management’s estimates requires the exercise of judgment. We believe
the following critical accounting policies affect its more significant judgments and estimates used in the preparation of financial
statements.
Going Concern – The financial statements have been
prepared assuming the Company will continue as a going concern. The Company has incurred net losses and negative operating cash
flow. To the extent the Company may have negative cash flows in the future it will continue to require additional capital to fund
operations. The Company obtained additional capital investments under various debt and common stock issuances. Although management
continues to pursue its financing plans, there is no assurance that the Company will be successful in obtaining sufficient revenues
to generate positive cash flow. The financial statements do not include any adjustments that might result from the outcome of these
uncertainties.
Principles of Consolidation – The consolidated
financial statements include the accounts of the Company and its wholly-owned or controlled operating subsidiaries. All intercompany
accounts and transactions have been eliminated.
Use of Estimates – The preparation of financial
statements in conformity with accounting principles generally accepted in the United States of America requires management to make
estimates and assumptions that affect reported amounts of assets and liabilities and disclosure of contingent assets and liabilities
at the date of the financial statements and the reported amounts of income and expenses during the reporting period. Actual results
could differ from those estimates.
Cash and Cash Equivalents – For purposes of the
Statement of Cash Flows, the Company considers highly liquid investments purchased with an original maturity of three months or
less to be cash equivalents.
Accounts Receivable – We estimate credit loss reserves
for accounts receivable on an individual receivable basis. A specific impairment allowance reserve is established based on expected
future cash flows and the financial condition of the debtor. We charge off customer balances in part or in full when
it is more likely than not that we will not collect that amount of the balance due. We consider any balance unpaid after
the contract payment period to be past due. There are $12,287 and $77,287 in Accounts receivables net of allowances
of $23,705 and $23,705 at June 30, 2019 and 2018, respectively.
Recognition of Revenues – In May 2014, the FASB
issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606). ASU 2014-09 establishes a single comprehensive model
for entities to use in accounting for revenue arising from outside contracts with customers and supersedes most of the existing
revenue recognition guidance and notes that lease contracts with customers are a scope exception. ASU 2014-09 requires an entity
to recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to
which an entity expects to be entitled in exchange for those goods or services and also requires certain additional disclosures.
On August 12, 2015, the FASB issued ASU 2015-14 to defer the effective date of ASU 2014-09. Public business entities may elect
to adopt the amendments as of the original effective date; however, adoption is required for annual reporting periods beginning
after December 15, 2017. The Company implemented this pronouncement as of July 1,2015.
The Company’s revenues are derived principally from utilizing
new technology in the medical alarm industry to provide 24-hour personal response monitoring services and related products to subscribers
with medical- or age-related conditions. The Company recognizes revenue when it is realized or realizable and earned. The Company
considers revenue realized or realizable and earned when it has persuasive evidence of an arrangement that the services have been
rendered to the customer, the sales price is fixed or determinable, and collectability is reasonably assured. All revenues from
subscription arrangements are recognized ratably over the term of such arrangements. The excess of amounts received over the income
recognized is recorded as deferred revenue on the consolidated balance sheet. As of June 30, 2019 and 2018, the Company recognized
$770,396 and $976,003 in revenue and recorded $196,058 and $215,880 in deferred revenue, respectively.
Basis of Consolidation – The Consolidated Financial
Statements include the accounts of Wearable Healthcare Solutions Inc. and all of our controlled subsidiary companies. All significant
intercompany accounts and transactions have been eliminated. Operating results of acquired businesses are included in the Consolidated
Statements of Income from the date of acquisition.
Deferred Taxes – The Company accounts for income
taxes under Section 740-10-30 of the FASB Accounting Standards Codification. Deferred income tax assets and liabilities are determined
based upon differences between the financial reporting and tax bases of assets and liabilities and are measured using the enacted
tax rates and laws that will be in effect when the differences are expected to reverse. Deferred tax assets are reduced by a valuation
allowance to the extent management concludes it is more likely than not that the assets will not be realized. Deferred tax assets
and liabilities are measured using enacted rates expected to apply to taxable income in the years in which those temporary differences
are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized
in the statements of operations in the period that includes the enactment date.
ASC 740, Income Taxes, requires a company to first determine
whether it is more likely than not (which is defined as a likelihood of more than fifty percent) that a tax position will be sustained
based on its technical merits as of the reporting date, assuming that taxing authorities will examine the position and have full
knowledge of all relevant information. A tax position that meets this more-likely-than-not threshold is then measured and recognized
at the largest amount of benefit that is greater than fifty percent likely to be realized upon effective settlement with a taxing
authority.
The Federal and state income tax returns of the Company for
2019, 2018, and 2017 are subject to examination by the Internal Revenue Service and state taxing authorities for three (3) years
from the date filed.
Related party transactions. The Company follows subtopic
850-10 of the FASB Accounting Standards Codification for the identification of related parties and disclosure of related party
transactions. Pursuant to Section 850-10-20 the related parties include:
|
a.
|
Affiliates
of the Company;
|
|
b.
|
Entities
for which investments in their equity securities would be required, absent the election of the fair value option under the Fair
Value Option Subsection of Section 825-10-15, to be accounted for by the equity method by the investing entity;
|
|
c.
|
Trusts
for the benefit of employees, such as pension and profit sharing trusts that are managed by or under the trusteeship of management;
|
|
d.
|
Principal
owners of the Company;
|
|
e.
|
Management
of the Company;
|
|
f.
|
Other
parties with which the Company may deal if one party controls or can significantly influence the management or operating policies
of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests;
and
|
|
g.
|
Other
parties that can significantly influence the management or operating policies of the transacting parties or that have an ownership
interest in one of the transacting parties and can significantly influence the other to an extent that one or more of the transacting
parties might be prevented from fully pursuing its own separate interests.
|
The financial statements include disclosures of material related
party transactions, other than compensation arrangements, expense allowances and other similar items in the ordinary course of
business. However, disclosure of transactions that are eliminated in the preparation of financial statements is not required in
those statements. The disclosures shall include:
|
a.
|
The
nature of the relationship involved;
|
|
b.
|
A
description of the transactions, including transactions to which no amounts or nominal amounts were ascribed for each of the periods
for which income statements are presented, and such other information deemed necessary to an understanding of the effects of the
transactions on the financial statements;
|
|
c.
|
The
dollar amount of transactions for each of the periods for which income statements are presented and the effects of any change
in the method of establishing the terms from that used in the preceding period; and
|
|
d.
|
Amounts
due from or to related parties as of the date of each balance sheet presented and, if not otherwise apparent, the terms and manner
of settlement.
|
Commitments and Contingencies. The Company follows subtopic
450-20 of the FASB Accounting Standards Codification to report accounting for contingencies. Certain conditions may exist as of
the date the financial statements are issued, which may result in a loss to the Company but which will only be resolved when one
or more future events occur or fail to occur. The Company assesses such contingent liabilities, and such assessment inherently
involves an exercise of judgment. In assessing loss contingencies related to legal proceedings that are pending against the Company
or unasserted claims that may result in such proceedings, the Company evaluates the perceived merits of any legal proceedings or
unasserted claims as well as the perceived merits of the amount of relief sought or expected to be sought therein.
If the assessment of a contingency indicates that it is probable
that a material loss has been incurred and the amount of the liability can be estimated, then the estimated liability would be
accrued in the Company’s financial statements. If the assessment indicates that a potentially material loss contingency is
not probable but is reasonably possible, or is probable but cannot be estimated, then the nature of the contingent liability, and
an estimate of the range of possible losses, if determinable and material, would be disclosed. Loss contingencies considered remote
are generally not disclosed unless they involve guarantees, in which case the guarantees would be disclosed. Management does not
believe, based upon information available at this time that these matters will have a material adverse effect on the Company’s
financial position, results of operations or cash flows. However, there is no assurance that such matters will not materially and
adversely affect the Company’s business, financial position, and results of operations or cash flows.
Fair value of financial instruments. The Company measures
its financial and non-financial assets and liabilities, as well as makes related disclosures, in accordance with FASB Accounting
Standards Codification No. 820, Fair Value Measurement (“ASC 820”), which provides guidance with respect to valuation
techniques to be utilized in the determination of fair value of assets and liabilities. Approaches include, (i) the market approach
(comparable market prices), (ii) the income approach (present value of future income or cash flow), and (iii) the cost approach
(cost to replace the service capacity of an asset or replacement cost). ASC 820 utilizes a fair value hierarchy that prioritizes
the inputs to valuation techniques used to measure fair value into three broad levels. The following is a brief description of
those three levels:
Level 1: Observable inputs such as quoted prices
(unadjusted) in active markets for identical assets or liabilities.
Level 2: Inputs other than quoted prices that
are observable, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets
and quoted prices for identical or similar assets or liabilities in markets that are not active.
Level 3: Unobservable inputs in which little
or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation
techniques in which one more significant inputs or significant value drivers are unobservable.
From time to time, our financial instruments include cash, accounts
payable and accrued expenses, convertible notes, lines of credit, and credit cards.
Software Development Costs. Software development costs
include payroll, employee benefits, stock-based compensation expense, and other headcount-related expenses associated with product
development. Software development costs also include third-party development and programming costs, localization costs incurred
to translate software for international markets, and the amortization of purchased software code and services content. Such costs
related to software development are included in research and development expense until the point that technological feasibility
is reached, which for our software products, is generally shortly before the products are released to production. Once technological
feasibility is reached, such costs are capitalized and amortized to cost of revenue over the estimated lives of the products.
Risk and Uncertainties. The Company is subject to risks
common to companies in the service industry, including, but not limited to, litigation, development of new technological innovations
and dependence on key personnel.
Off-Balance Sheet Arrangements. The Company does not
have any off-balance sheet arrangements.
Uncertain Tax Positions. The Company did not take any
uncertain tax positions and had no adjustments to unrecognized income tax liabilities or benefits pursuant to the provisions of
Section 740-10-25 for the years ended September 30, 2018 or 2017.
Recent Accounting Pronouncements
In May 2014, the Financial Accounting Standards Board
(“FASB”) issued Accounting Standard Update (“ASU”) 2014-09, Revenue from Contracts with Customers
(Topic 606), a new standard on revenue recognition. Further, the FASB issued a number of additional ASUs regarding the new
revenue recognition standard. The new standard, as amended, will supersede existing revenue recognition guidance and apply to
all entities that enter into contracts to provide goods or services to customers. In August 2015, the FASB issued
ASU 2015-14, Revenue from Contracts with Customers – Deferral of the Effective Date, which amends ASU 2014-09
to defer the effective date by one year. For public companies, the new standard is effective for annual reporting periods
beginning after December 31, 2017, including interim periods within that reporting period. For all other entities,
including emerging growth companies, this standard is effective for annual reporting periods beginning after
December 15, 2018, and interim reporting periods within annual reporting periods beginning after December 15, 2019. The
Company is evaluating the impact on the financial statements and expects to implement the provisions of ASU 2014-09 for
the annual financial statements for the year ended June 30, 2016.
In January 2016, the FASB issued ASU 2016-01, Financial Instruments
– Overall (Subtopic 825-10) – Recognition and Measurement of Financial Assets and Financial Liabilities, which
requires all investments in equity securities with readily determinable fair value to be measured at fair value with changes in
the fair value recognized through net income (other than those accounted for under the equity method of accounting or those that
result in consolidation of the investee). ASU 2016-01 is intended to enhance the reporting model for financial instruments
to provide users of financial statements with more decision-useful information and removes the requirement to disclose the methods
and significant assumptions used to estimate the fair value for financial instruments measured at amortized cost on the balance
sheet. For public companies, the new standard is effective for annual periods beginning after December 15, 2017, including interim
periods within the fiscal year. For all other entities, including emerging growth companies, ASU 2016-01 is effective for annual
periods beginning after December 15, 2018, and interim periods within annual periods beginning after December 15, 2019.
The Company evaluated the impact on the financial statements and implemented the provisions of ASU 2016-01 for the annual
financial statements for the year ended June 30, 2019.
In February 2016, the FASB issued ASU 2016-02, Leases (Topic
842), which supersedes the current accounting for leases and while retaining two distinct types of leases, finance and operating,
(1) requires lessees to record a right of use asset and a related liability for the rights and obligations associated with
a lease, regardless of lease classification, and recognize lease expense in a manner similar to current accounting, (2) eliminates
most real estate specific lease provisions, and (3) aligns many of the underlying lessor model principles with those in the
new revenue standard. Leases with a term of 12 months or less will be accounted for similar to existing guidance for operating
leases today. For public companies, the new standard is effective for annual and interim periods in fiscal years beginning after
December 15, 2018. For all other entities, including emerging growth companies, this standard is effective for annual reporting
periods beginning after December 15, 2019, and interim periods within fiscal years beginning after December 2020. Earlier application
is permitted. The Company evaluated the impact on the financial statements and implemented the provisions of ASU 2016-02 for the
annual financial statements for the year ended June 30, 2019.
In June 2016, the FASB issued ASU 2016-13, Financial Instruments
– Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. ASU 2016-13 requires the measurement
of all expected credit losses for financial assets held at the reporting date based on historical experience, current conditions
and reasonable and supportable forecasts. Adoption of ASU 2016-13 will require financial institutions and other organizations to
use forward-looking information to better formulate their credit loss estimates. In addition, the ASU amends the accounting
for credit losses on available-for-sale debt securities and purchased financial assets with credit deterioration. This update will
be effective for fiscal years beginning after December 15, 2020 and interim periods within fiscal years beginning after December
15, 2021. The Company is evaluating the impact on the financial statements and expects to implement the provisions
of ASU 2016-13 for the annual financial statements for the interim periods beginning July 1, 2021.
In January 2017, the FASB issued ASU 2017-01, which changes
the definition of a business. The new guidance requires an entity to first evaluate whether substantially all of the fair value
of the gross assets acquired is concentrated in a single identifiable asset or a group of similar identifiable assets. If that
threshold is met, the set of assets and activities is not a business. If it is not met, the entity evaluates whether the set meets
the definition of a business. The new definition requires a business to include at least one substantive process and narrows the
definition of outputs by more closely aligning it with how outputs are described in the new revenue recognition guidance. The new
guidance is effective for public business entities for fiscal years beginning after 15 December 2017, and interim periods within
those years. For all other entities, it is effective for fiscal years beginning after 15 December 2018, and interim periods within
fiscal years beginning after 15 December 2019. The ASU will be applied prospectively to any transactions occurring within the period
of adoption. Early adoption is permitted, including for interim or annual periods for which the financial statements have not been
issued or made available for issuance. The Company implemented this for the year ended June 30, 2019.
In August 2018, the FASB issued ASU 2018-13, Disclosure Framework
– Changes to the Disclosure Requirements for Fair Value Measurement (Topic 820). ASU 2018-13 adds, modifies, and removes
certain fair value measurement disclosure requirements. ASU 2018-13 is effective for annual and interim periods beginning after
December 15, 2019. Early adoption is permitted. The Company evaluated the impact on the financial statements and has implemented
the provisions of ASU 2018-13 as of June 30, 2019.
The Company reviewed all recent accounting pronouncements issued
by the FASB (including its Emerging Issues Task Force), the AICPA and the SEC, and they did not or are not believed by management
to have a material impact on the Company’s present or future financial statements.
Note 3 – Going Concern
The accompanying financial statements for the years ended June
30, 2019 and 2018 have been prepared on a going concern basis, which contemplates the realization of assets and the settlement
of liabilities and commitments in the normal course of business. As of June 30, 2019, the Company has shown losses for the last
2 years, and has an accumulated deficit of ($18,925,157). Management believes that the Company’s capital requirements will
depend on many factors, including the success of the Company’s development efforts and its efforts to raise capital. Management
also believes the Company needs to raise additional capital for working capital purposes. There can be no assurance that the Company
will be able to obtain the additional capital resources necessary to implement its business plan or that any assumptions relating
to its business plan will prove accurate.
These factors raise substantial doubt about the Company’s
ability to continue as a going concern. The financial statements of the Company do not include any adjustments relating to the
recoverability and classification of recorded assets, or the amounts and classifications of liabilities that might be necessary
should the Company be unable to continue as a going concern.
Note 4 – Inventory and prepaid expenses
The Company maintains some inventory in-house and purchases
some of its inventory overseas. Inventory, except for stock-in-transit, is stated at lower of cost and net realizable value. Stock-in-transit
is valued at cost, comprising invoice value plus other charges thereon. Net realizable value is the estimated selling price in
the ordinary course of business, less estimated costs of completion and selling expenses. The quantity of inventory may vary from
time to time depending on the delivery schedule of overseas shipments.
|
|
2019
|
|
2018
|
Finished goods
|
|
$
|
5,254
|
|
|
$
|
91,287
|
|
Prepaid inventory in transit
|
|
|
91,013
|
|
|
|
43,316
|
|
Inventory
|
|
$
|
96,267
|
|
|
$
|
134,603
|
|
As of June 30, 2019 and 2018, the Company had $5,254 and $91,287
in inventory in-house, respectively, as well as $91,013 and $43,316 in prepaid inventory in transit, respectively.
Note 5 – Property, Plant, and Equipment
The Company has $20,000 in furnishings, which are fully depreciated,
$19,689 in office computers and equipment, which are fully depreciated, and capitalized software development costs of $45,900,
which are partially depreciated.
As of June 30, 2019 and 2018, the Company recorded $6,118 and
$13,607 in Property, Plant, and Equipment, respectively:
|
|
2019
|
|
2018
|
Furniture
|
|
$
|
20,000
|
|
|
$
|
20,000
|
|
Office computers, equipment, software
|
|
|
19,689
|
|
|
|
19,689
|
|
Software development costs
|
|
|
45,900
|
|
|
|
45,900
|
|
Property, plant, and equipment
|
|
|
85,589
|
|
|
|
85,589
|
|
Less accumulated depreciation
|
|
|
(79,471
|
)
|
|
|
(71,982
|
)
|
Net property, plant, and equipment
|
|
$
|
6,118
|
|
|
$
|
13,607
|
|
Note 6 – Accounts payable and accrued expenses and
liabilities
The Company recorded Accounts Payable of $222,924 and $93,758
directly related to operating costs, including credit cards used in operations, as of June 30, 2019 and 2018, respectively.
Accrued expenses are expenses that have been incurred but not
yet paid and mainly include legal fees, audit fees, and other professional fees, as well as interest accrued in connection with
credit lines. The Company recorded $412,102 and $197,370 in accrued expenses and other current liabilities as of June 30, 2019
and 2018, respectively.
Note 7 – Notes Payable and Note Payable – Other
Notes Payable:
In 2019, the Company negotiated a fixed repayment settlement
of some of its debt of $70,875 on a non-interest bearing basis. The Company has various loans and credit lines outstanding. The
credit line carries an interest rate of 16.24%. The bank loans carry interest rates varying between 9.24% – 10.90%.
|
|
2019
|
|
2018
|
Kabbage
|
|
$
|
11,842
|
|
|
$
|
24,604
|
|
1st Merchant
|
|
|
–
|
|
|
|
24,511
|
|
Wells Fargo
|
|
|
33,970
|
|
|
|
34,121
|
|
Prosper
|
|
|
28,327
|
|
|
|
–
|
|
Debt settlement
|
|
|
70,875
|
|
|
|
–
|
|
Total Notes Payable
|
|
$
|
145,014
|
|
|
$
|
83,236
|
|
As of June 30, 2019 and 2018, the Company has outstanding $145,014
(including the above-referenced $70,875) and $83,236 in bank loans and credit lines payable, respectively.
Note Payable – Other
In June 2018, the Company secured a $50,000 line of credit from
Emry Capital, bearing interest at 8% per annum and convertible into shares of the Company’s capital stock pursuant to the
default provisions of the line with a cost of $3,000, which was fully amortized. Originally, the Company earmarked these funds
exclusively towards the successful VR product line development and integration.
The note that memorialized the line of credit has been sold
several times, and, in November 2019, the note was acquired by Mr. Mittler and Mr. Pizzino, who forgave the obligation (See Note
15).
As of June 30, 2019 and 2018, the Company recorded Note Payable
– Other of $53,000 and $50,000, respectively.
Note 8 -- Convertible Notes Payable (March 2016)
On March 1, 2016 and March 3, 2016, the Company closed a private
placement and received an aggregate of $612,500 by selling $660,000 and $13,750 unsecured convertible notes (“March Convertible
Notes”) and granted warrants (“March Warrants”) to two investors, net of an aggregate original issue discount
of $61,250 pursuant to the terms of the related subscription agreements. The March Convertible Notes bear no interest and are due
one year from the date of issuance. The March Convertible Notes are convertible into shares of the Company’s common stock
at a conversion price equal to $0.01 per share. The Warrants are exercisable for the purchase of up to 6,804,172 shares of the
Company’s Series C Convertible Preferred Stock at $0.09 per share. The conversion price of the March Convertible Notes and
the exercise price of the March Warrants are subject to adjustment under certain circumstances. The Company is prohibited from
effecting a conversion of the March Convertible Notes into shares of common stock and a conversion of shares of Series C Convertible
Preferred Stock (if the March Warrants were exercised) into shares of common stock, if, as a result of any such conversion, the
investor would beneficially own more than 4.99% of the number of shares of Common Stock outstanding immediately after giving effect
to the issuance of shares of Common Stock upon either or both conversions, which beneficial ownership limitation may be increased
by the investor up to, but not exceeding, 9.99%.
The Company has determined that the conversion feature embedded
in the March Convertible Notes constitutes a derivative and has been bifurcated from the March Convertible Notes and recorded as
a derivative liability, with a corresponding discount recorded to the associated debt, on the accompanying balance sheet, and revalued
to fair market value at each reporting period. As of June 30, 2019, the remaining debt discount balance of $76,250 has been amortized
and the Company recognized the full loan balance due of $673,750.
Note
9 – Warrants (March 2016)
The Company has evaluated the application of ASC 815 Derivatives
and Hedging and ASC 815-40-25 to the March Warrants to purchase Series C Convertible Preferred Stock. Based on the guidance in
ASC 815 and ASC 815-40-25, the Company concluded these instruments were required to be accounted for as derivatives due to the
down-round protection features on the exercise price and the conversion price. The Company records the fair value of these derivatives
on its balance sheet at fair value with changes in the values of these derivatives reflected in the statements of operations as
“Change in fair value of derivative instrument” These derivative instruments are not designated as hedging instruments
under ASC 815 and are disclosed on the balance sheet under Derivative Liabilities.
The fair value of the March Warrants at the time of their issuance
was calculated pursuant to the Black-Scholes option pricing model. The fair value was recorded as a reduction to the convertible
notes payable and was charged to operations as interest expense in accordance with effective interest method within the period
of the March Convertible Notes with expiration March 2019. No March Warrants were exercised during the period, and as of June 30,
2019, all then-outstanding March Warrants have expired.
Note 10 – Stockholders’ Equity (Deficit)
Capital Stock:
The Company is currently authorized to issue 1,200,000,000
shares of common stock, par value of $0.0001 per share, and 14,000,000 shares of preferred stock, par value of $0.0001 per share.
During the period ended June 30, 2019, the Company issued 41,320,501
shares of common stock for services, valued at $4,132 or $0.0001 per share, and sold 3,500,000 shares of common stock to an unrelated
party for $25,000, valued at $0.00714 per share.
As of June 30, 2019 and 2018, the Company had 94,699,177 and
49,878,676 shares of common stock issued and outstanding, respectively.
Preferred Stock:
Series A Convertible Preferred Stock: The Company
is currently authorized to issue up to 100,000 shares of Series A Convertible Preferred Stock, par value $0.0001 per share, convertible
at a ratio of 1 share of Series A Convertible Preferred Stock for 2 shares of common stock. These shares have no voting rights.
As of June 30, 2019 and 2018, 688 shares of Series A Convertible Preferred Stock were issued and outstanding, respectively.
Series B Convertible Preferred Stock: The Company
is currently authorized to issue up to 62,500 shares of Series B Convertible Preferred Stock, par value $0.0001 per share, convertible
at a ratio of 1 share of Series B Convertible Preferred Stock for 2 shares of common stock. These shares have no voting rights.
As of June 30, 2019 and 2018, 9,938 shares of Series B Convertible Preferred Stock were issued and outstanding, respectively.
Series C Convertible Preferred Stock: The Company
is currently authorized to issue up to 6,944,445 shares of Series C Convertible Preferred Stock, par value $0.0001 per share, convertible
at a ratio of 1 share of Series C Convertible Preferred Stock for 10 shares common stock. These shares have no voting rights. As
of June 30, 2019 and 2018, 138,886 shares of Series C Convertible Preferred Stock were issued and outstanding, respectively.
Series D Convertible Preferred Stock: The
Company is currently authorized to issue up to 500,000 shares of Series D Convertible Preferred Stock, par value $0.0001 per share,
convertible at a ratio of 1 share of Series D Convertible Preferred stock for 10 shares of common stock. These shares have no voting
rights. As of June 30, 2019 and 2018, 425,000 shares of Series D Convertible Preferred Stock were issued and outstanding, respectively.
Series E Convertible Preferred Stock: The
Company is currently authorized to issue up to 5,000,000 shares of Series E Convertible Preferred Stock, par value $0.0001 per
share, convertible at a ratio of 1 share of Series E Convertible Preferred Stock for 100 shares of common stock. Each of these
shares carries a voting right equivalent to 10,000 shares of common stock. The Company may not issue any other shares with extended
voting rights. As of June 30, 2019 and 2018, 4,000,000 and -0- shares of Series E Convertible Preferred Stock were issued and outstanding,
respectively.
In October 2018, the Company sold and issued 4,000,000 shares
of Series E Convertible Preferred Stock to an otherwise unrelated third party for $400, or $0.0001 per share. Since these shares
carry voting rights of an aggregate of 40,000,000,000 shares of common stock, which constituted more than the aggregate number
of issued and outstanding shares of the Company’s other capital stock, this sale and issuance constituted a change of control
in the Company. These shares were resold in a private transaction on August 27, 2018, and resold again in another private transaction
on October 26, 2018. In November 2019, these shares were acquired in a subsequent private transaction by Mr. Mittler and Mr. Pizzino,
together with 200,000,000 shares of common stock, when then vested in them control of the Company. In connection with the acquisition
of such shares, Mr. Mittler and Mr. Pizzino also acquired the $53,000 Emry Capital note. As of November 2019, all of shares were
to be returned to treasury for cancellation, and the debt was to be forgiven (see Note 15).
Note 11 – Related Party Transactions
Credit line – related party
On September 30, 2014, the Company received a line of credit
with Medi Pendant New York, Inc. (“MNY”), which is partially owned by the Company’s CEO. Under the line of credit
agreement, the Company will be able to borrow up to $500,000 with the rate of interest of 6.5% per annum. The maturity date of
the line of credit is September 30, 2017 with a one-year extension to September 30, 2018. On January 31, 2015, the limit on the
line of credit was increased to $500,000 with same interest rate and due date, in consideration of the Company’s issuance
of 200,000 shares of common stock to one of the owners of MNY, which was memorialized on October 19, 2015. As of June 30, 2019
and 2018, the Company recorded line of credit balances of $397,500 and $397,500, respectively.
Related party loans
In 2019 and 2018, from time to time, related parties lent to
the Company funds for day-to-day operations. These are short-term loans which bear no interest, and the Company expects to repay
these loans by the end of the fiscal year following the year in which the short-term loan was made
|
|
2019
|
|
2018
|
Due to management
|
|
$
|
85,716
|
|
|
$
|
7,400
|
|
Due to other related parties
|
|
|
29,996
|
|
|
|
–
|
|
Total loans from related parties
|
|
$
|
113,712
|
|
|
$
|
7,400
|
|
As of June 30, 2019 and 2018, the Company owes $113,713 and
$7,400 in related party loans, respectively.
Note 12 – Net Income(Loss) Per Share
Income (loss) per share is computed by dividing the net income
(loss) by the weighted average number of common shares outstanding during the period. Diluted income (loss) per share reflects
the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into
common stock or resulted in the issuance of common stock that would then share in the net income of the Company, subject to anti-dilution
limitations.
|
|
Basis of conversion
|
|
Dilution
|
|
2019
|
|
2018
|
March Convertible Notes
|
|
$673,750
|
|
Share price of $0.01
|
|
|
67,375,300
|
|
|
|
67,375,300
|
|
Series A Convertible
|
|
688 shares outstanding
|
|
1 share A: 2 shares
|
|
|
1,288
|
|
|
|
1,288
|
|
Series B Convertible
|
|
9,938 shares outstanding
|
|
1 share B: 2 shares
|
|
|
19,876
|
|
|
|
19,876
|
|
Series C Convertible
|
|
138,886 shares outstanding
|
|
1 share C: 10 shares
|
|
|
1,388,860
|
|
|
|
1,388,860
|
|
Series D Convertible
|
|
425,000 shares outstanding
|
|
1 share D: 10 shares
|
|
|
4,250,000
|
|
|
|
4,250,000
|
|
Series E Convertible
|
|
4,000,000 shares outstanding
|
|
1 share E: 100 shares
|
|
|
400,000,000
|
|
|
|
–
|
|
|
|
|
|
|
|
|
473,035,412
|
|
|
|
73,035,412
|
|
Because the Company posted losses for the past two years, the
basic and diluted share bases will be presented as the same. For the years ended June 30, 2019 and 2018, the Company posted losses
of ($.00828) and ($0.005590) per basic share and diluted share, respectively.
Note 13 – Revenue and expenses
The Company’s wholly owned subsidiary generated the following
revenues and incurred the following expenses for the years ended June 30, 2019, and 2018, respectively.
REVENUES
|
|
2019
|
|
2018
|
Lock box sales
|
|
$
|
–
|
|
|
$
|
763
|
|
Service labor
|
|
|
50
|
|
|
|
597
|
|
Med01 kit
|
|
|
969
|
|
|
|
109,915
|
|
Replacement parts
|
|
|
210
|
|
|
|
705
|
|
Accessory sales
|
|
|
–
|
|
|
|
4,114
|
|
Other service
|
|
|
115,796
|
|
|
|
12,668
|
|
Shipping, handling & reimbursable expenses
|
|
|
–
|
|
|
|
2,486
|
|
|
|
|
770,396
|
|
|
|
976,003
|
|
LESS: COST OF GOODS SOLD
|
|
|
398,167
|
|
|
|
261,498
|
|
GROSS PROFIT
|
|
$
|
372,229
|
|
|
$
|
714,506
|
|
|
|
|
|
|
|
|
|
|
EXPENSES
|
|
|
|
|
|
|
|
|
Selling expenses
|
|
$
|
25,847
|
|
|
$
|
34,361
|
|
Consulting
|
|
|
39,467
|
|
|
|
30,107
|
|
Payroll
|
|
|
304,404
|
|
|
|
413,527
|
|
Payroll taxes
|
|
|
190,816
|
|
|
|
165,212
|
|
Professional services
|
|
|
26,277
|
|
|
|
51,692
|
|
Software
|
|
|
52,833
|
|
|
|
63,510
|
|
Other general & administrative
|
|
|
132,197
|
|
|
|
200,460
|
|
|
|
|
771,841
|
|
|
|
958,869
|
|
Interest expense
|
|
|
17,495
|
|
|
|
34,378
|
|
TOTAL EXPENSES
|
|
$
|
789,336
|
|
|
$
|
993,247
|
|
NET LOSS
|
|
$
|
(417,107
|
)
|
|
$
|
(278,741
|
)
|
Note 14 – Income Taxes
Deferred income tax assets and liabilities are computed annually
for differences between financial statement and tax bases of assets and liabilities that will result in taxable or deductible amounts
in the future based on enacted tax laws and rates applicable to the periods in which the differences are expected to affect taxable
income. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized.
Income tax expense is the tax payable or refundable for the period plus or minus the change during the period in deferred tax assets
and liabilities.
The effective tax rate on the net loss before income taxes differs
from the U.S. statutory rate as follows:
|
|
June 30, 2019
|
|
June 30, 2018
|
U.S. statutory rate
|
|
21%
|
|
21%
|
Less valuation allowance
|
|
(21%)
|
|
(21%)
|
Effective tax rate
|
|
0%
|
|
0%
|
The significant components of deferred tax assets and liabilities
are as follows, expiring in 2023 and 2024, on net operating losses of $18,925,157 and $18,209,695 for fiscal years ended June 30,
2019 and 2018, respectively:
|
|
June 30, 2019
|
|
June 30, 2018
|
Net deferred tax assets
|
|
$
|
3,974,283
|
|
|
$
|
3,824,036
|
|
Less valuation allowance
|
|
|
(3,974,283
|
)
|
|
|
(3,824,036
|
)
|
Deferred tax asset - net valuation allowance
|
|
|
-0-
|
|
|
|
-0-
|
|
Note 15 – Subsequent Events
Series E Convertible Preferred Stock:
On October 19, 2018, the Company issued 4,000,000 shares of
Series E Convertible Preferred Stock to Mina Mar Group Corporation for $400, or $.0001 per share. Each of these shares carries
a voting right equivalent to 10,000 shares of common stock, which issuance constituted a change of control of the Company.
In August 2019, Mina Mar Group Corporation sold the 4,000,000
shares of Series E Convertible Preferred Stock to IMASK, which sale constituted a change in control. After that change in control,
the Company issued 200,000,000 shares of its common stock, par value $0.0001, to IMASK for services rendered, valued at $20,000.
IMASK then sold the shares Series E Convertible Preferred Stock and 200,000,000 shares of common stock to Mr. Mittler and Mr. Pizzino
for $135,000 and assigned to Mr. Mittler and Mr. Pizzino the $53,000 Emry Note. Mr. Mittler and Mr. Pizzino subsequently returned
all of the Series E Convertible Preferred Stock and the common stock to the Company for cancelation and forgave the $53,000 Emry
Note. Leonite Capital LLC funded the Series E Convertible Preferred Stock, the common stock, and Emry Note transaction, encumbering
the Company, as well as its co-maker Hypersoft Ventures, with $150,000 convertible note, convertible to common stock of the Company
at the lower of $0.02 per share or 50% of the lowest bid price during the twenty-one (21) consecutive trading-day period immediate
preceding the trading day on which the Company receives the notice of conversion or the discount to market based on subsequent
financing. Leonite also received 2,500,000 shares of common stock in connection with the funding.
Convertible Note: Leonite Capital, LLC:
On November 19, 2019, the Company, together with Hypersoft Ventures
(collectively, the “Borrower”), received $135,000 on issuing the first tranche of $150,000 (prorated original issue
discount of $15,000) of a $250,000 unsecured convertible note (“Leonite Convertible Note”) to Leonite Capital, LLC,
a Delaware limited liability company (“Leonite”), net of an aggregate original issue discount of up to $77,778. The
Leonite Convertible Note bears annual interest at the Prime Rate plus eight percent (8%), not to exceed twelve percent (12%) per
annum, computed on a 365/360 basis, and is due nine months from the date of issuance. The Leonite Convertible Note is convertible
into shares of the Company’s common stock at a conversion price equal to $0.02 per share with anti-dilution features. In
connection with its purchase of the Leonite Convertible Note, the Company issued to Leonite 2,500,000 shares of common stock, prorated
for the initial tranche.
The Company has determined that the conversion feature embedded
in the Leonite Convertible Note constitutes a derivative and has been bifurcated from the Leonite Convertible Note and recorded
as a derivative liability, with a corresponding discount recorded to the associated debt, on the accompanying balance sheet, and
revalued to fair market value at each reporting period. The initial issuance yielded a derivative liability of $94,225, with a
discount of $150,000 to be amortized over the 9-month life of the Leonite Convertible Note.
Significant assumptions used in calculating fair value of conversion
feature of Leonite Convertible Note at issuance date are as follows.
Expected Dividends
|
|
Expected volatility
|
|
Risk-free rate of interest
|
|
Expected term (year)
|
|
Exercise
(Conversion)
price
|
|
Common stock price per share
|
|
0.00
|
%
|
|
|
809.71
|
%
|
|
|
0.0154
|
%
|
|
|
0.75
|
|
|
$
|
0.02
|
|
|
$
|
0.01300
|
|
Revaluation at December 31, 2019 yielded a gain of $25,222 on
change in fair value of derivative liability, amortization of discounts of $23,889, and interest expense of $2,256.
Balance at September 30, 2019
|
|
$
|
–
|
|
Leonite Convertible Note issued
|
|
|
150,000
|
|
Leonite Convertible Note converted
|
|
|
–
|
|
Total
|
|
|
150,000
|
|
Less: debt discount
|
|
|
(126,111
|
)
|
Balance at December 31, 2019
|
|
$
|
23,889
|
|
Significant assumptions used in calculating fair value of conversion
feature of Leonite Convertible Note as of March 31, 2020 are as follows.
Expected Dividends
|
|
Expected volatility
|
|
Risk-free rate of interest
|
|
Expected term (year)
|
|
Exercise
(Conversion)
price
|
|
Common stock price per share
|
|
0.00
|
%
|
|
|
826.28
|
%
|
|
|
0.0159
|
%
|
|
|
0.667
|
|
|
$
|
0.02
|
|
|
$
|
0.00950
|
|
Revaluation at March 31, 2020 yielded a loss of $230,349 on
change in fair value of derivative liability, primarily due to default on the Leonite Convertible Note and change in conversion
price, amortization of $50,556, and interest and late fees expense of $4,778.
Balance at March 31, 2020
|
|
$
|
–
|
|
Leonite Convertible Note issued
|
|
|
150,000
|
|
Leonite Convertible Note converted
|
|
|
–
|
|
Total
|
|
|
150,000
|
|
Less: debt discount
|
|
|
(75,555
|
)
|
Balance at March 31, 2020
|
|
$
|
74,445
|
|
Significant assumptions used in calculating fair value of warrants
and conversion feature of convertible notes as of March 31, 2020 are as follows.
Expected Dividends
|
|
Expected volatility
|
|
Risk-free rate of interest
|
|
Expected
term (year)
|
|
Exercise
(Conversion)
price
|
|
Common stock price per share
|
|
0.00
|
%
|
|
|
845.05
|
%
|
|
|
0.0170
|
%
|
|
|
0.458
|
|
|
$
|
0.00250
|
|
|
$
|
0.0050
|
|